Abbott has obtained the European CE-Mark for its Architect Stat High Sensitive Troponin-I blood test designed to predict the chances of a heart attack or other cardiac events in seemingly healthy people.
The test uses a cardiac-specific biomarker to identify at-risk adults potentially months to years in advance.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Current European guidelines recommend analysis of indirect heart health factors such as cholesterol levels, blood pressure, diabetes or smoking status to establish the risk of a patient developing future heart disease.
Research showed that measuring a person’s troponin levels with Abbott’s new blood test can offer better predictive information when used in conjunction with the existing standard of care.
Abbott diagnostics business global medical and scientific affairs senior medical director Agim Beshiri said: “We finally have a heart-specific tool when trying to determine a patient’s chances of developing heart disease.
“This advancement has the potential to transform how doctors and patients prevent heart disease. Because the high sensitive troponin-I test can be part of any routine health check, it fits easily into existing healthcare practices.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe High Sensitive Troponin-I blood test has been studied over the past five years in emergency rooms across Europe for fast and accurate detection of heart attacks.
As the test can identify very low troponin levels, it is expected to be useful in people without any reported symptoms. It can be used during a routine health exam at the time of standard blood draw.
The information provided by the test can help doctors in delivering correct treatment for people at high risk. It can also avoid unnecessary tests, medication and costs for lower-risk patients.
